EUVIMEDEUVIMED entdecken
Editorial

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies

Zobair M Younossi

Clinics in Liver Disease · 2026-05 · 30 (2) · xix-xx

DOI: 10.1016/j.cld.2026.02.001 ↗

Kurz gefasst

Editorial in der Zeitschrift Clinics in Liver Disease, 2026-05. Verfasst von Zobair M Younossi. Beteiligte Einrichtung: The Global NASH/MASH Council (GNC), Center for Outcomes Research in Liver Diseases, Washington, DC, USA; The Global Center for Liver Outcomes & Polic….

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • The Global NASH/MASH Council (GNC), Center for Outcomes Research in Liver Diseases, Washington, DC, USA; The Global Center for Liver Outcomes & Policy Research, Georgetown University School of Medicine, Washington, DC,…

Zitieren

APA

Younossi, Z. M. (2026). Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies. Clinics in Liver Disease, 30(2), xix-xx. https://doi.org/10.1016/j.cld.2026.02.001

Vancouver

Younossi ZM. Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies. Clinics in Liver Disease. 2026;30(2):xix-xx. doi:10.1016/j.cld.2026.02.001

BibTeX
@article{Younossi2026,
  author = {Younossi, Zobair M},
  title = {Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies},
  journal = {Clinics in Liver Disease},
  year = {2026},
  volume = {30},
  number = {2},
  pages = {xix--xx},
  doi = {10.1016/j.cld.2026.02.001}
}
Kostenlos starten →